Literature DB >> 23466340

CFTR2: How will it help care?

Carlo Castellani1.   

Abstract

The Clinical and Functional Translation of CFTR (CFTR2) project presents a novel approach to clinical and functional annotation of mutations identified in disease-causing genes. Phenotype and genotype information on approximately 40,000 cystic fibrosis (CF) patients were collected from registries and large clinics. The disease-liability of the 160 most frequently reported mutations was evaluated by means of a multistage process which involved clinical (sweat chloride average), functional (expression in cell-based systems) and epidemiological (mutation analysis in obligate heterozygotes) steps. The results of this analysis can be consulted in a dedicated website. Data originated by CFTR2 may be valuable in several facets of CF care, including diagnosis, newborn screening, carrier testing, genotype/phenotype correlation and mutation-specific therapeutics.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23466340     DOI: 10.1016/j.prrv.2013.01.006

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  25 in total

Review 1.  The current state of clinical interpretation of sequence variants.

Authors:  Derick C Hoskinson; Adrian M Dubuc; Heather Mason-Suares
Journal:  Curr Opin Genet Dev       Date:  2017-01-31       Impact factor: 5.578

Review 2.  Impact of gene editing on the study of cystic fibrosis.

Authors:  Patrick T Harrison; David J Sanz; Jennifer A Hollywood
Journal:  Hum Genet       Date:  2016-06-21       Impact factor: 4.132

3.  A new method of sweat testing: the CF Quantum®sweat test.

Authors:  Michael J Rock; Linda Makholm; Jens Eickhoff
Journal:  J Cyst Fibros       Date:  2014-05-23       Impact factor: 5.482

Review 4.  Paediatric genomics: diagnosing rare disease in children.

Authors:  Caroline F Wright; David R FitzPatrick; Helen V Firth
Journal:  Nat Rev Genet       Date:  2018-02-05       Impact factor: 53.242

Review 5.  Precision Genomic Medicine in Cystic Fibrosis.

Authors:  Eugene H Chang; Joseph Zabner
Journal:  Clin Transl Sci       Date:  2015-06-15       Impact factor: 4.689

6.  Novel bioinformatics quality control metric for next-generation sequencing experiments in the clinical context.

Authors:  Maxim Ivanov; Mikhail Ivanov; Artem Kasianov; Ekaterina Rozhavskaya; Sergey Musienko; Ancha Baranova; Vladislav Mileyko
Journal:  Nucleic Acids Res       Date:  2019-12-02       Impact factor: 16.971

7.  Sources of Variation in Sweat Chloride Measurements in Cystic Fibrosis.

Authors:  Joseph M Collaco; Scott M Blackman; Karen S Raraigh; Harriet Corvol; Johanna M Rommens; Rhonda G Pace; Pierre-Yves Boelle; John McGready; Patrick R Sosnay; Lisa J Strug; Michael R Knowles; Garry R Cutting
Journal:  Am J Respir Crit Care Med       Date:  2016-12-01       Impact factor: 21.405

8.  Genomic sequencing in cystic fibrosis newborn screening: what works best, two-tier predefined CFTR mutation panels or second-tier CFTR panel followed by third-tier sequencing?

Authors:  Robert J Currier; Stan Sciortino; Ruiling Liu; Tracey Bishop; Rasoul Alikhani Koupaei; Lisa Feuchtbaum
Journal:  Genet Med       Date:  2017-05-04       Impact factor: 8.822

9.  Targeted mutation screening panels expose systematic population bias in detection of cystic fibrosis risk.

Authors:  Regine M Lim; Ari J Silver; Maxwell J Silver; Carlos Borroto; Brett Spurrier; Tanya C Petrossian; Jessica L Larson; Lee M Silver
Journal:  Genet Med       Date:  2015-04-16       Impact factor: 8.822

10.  Genomic, transcriptomic, and protein landscape profile of CFTR and cystic fibrosis.

Authors:  Morgan Sanders; James M J Lawlor; Xiaopeng Li; John N Schuen; Susan L Millard; Xi Zhang; Leah Buck; Bethany Grysko; Katie L Uhl; David Hinds; Cynthia L Stenger; Michele Morris; Neil Lamb; Hara Levy; Caleb Bupp; Jeremy W Prokop
Journal:  Hum Genet       Date:  2020-07-30       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.